JPRN-UMIN000013385已完成2 期
PhaseII study of 5-FU/I-LV+L-OHP+CPT-11 combination chemotherapy(FOLFIRINOX) in 1st line treatment for locally advanced pancreatic cancer - FOLFIRINOX
Osaka Medical College Hospital0 个研究点目标入组 45 人开始时间: 2014年3月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)with pulmonary fibrosis or interstital pneumonia which can be detected from X-ray incontrovertibly or has clinical symptom 2)with severe diarrhea within 3 days before entry 3)with other severe diseases(heart failure, renal disfunction, liver disfunction, intestinal paralysys, ileus, uncontrolled DM) 4)patients whom administered flucitosine or Fenitoin or Warfarin 5)with active double cancers whose disease free period is shorter than 5 years Carcinoma in situ can be excluded. 6)with infectious disease which needs therapy 7)with body temperature over 38 degrees Celsius 8)women who are pregnant or expect to be pregnant, or nursing female 9)patients whom doctor in chief decides not to register to this study due to psychological disease or symptoms 10)general administration of steroids 11)with grade 2 or more severe peripheral neuropathy 12)with UGT1A1*28 and/or UGT1A1*6 polymorphisms
研究者
相似试验
已完成
2 期
Phase II study of a combination of CPT-11, 5FU/l-LV and UFT/LV in patients with advanced/recurrent colorectal canceradvanced/recurrent colorectal cancerJPRN-UMIN000000613Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)40
未知
2 期
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal CancerJPRN-jRCT1080220199Taiho Pharmaceutical Co., Ltd. DAIICHI SANKYO Co., Ltd.
Unknown
3 期
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal CancerCancer of the RectumNCT00189657Association Européenne de Recherche en Oncologie
进行中（未招募）
1 期
A study of a new anti-CD47 antibody therapy with an approved therapy rituximab or Rituximab + Chemotherapy in patients with a cancer of B-cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentRelapsed/Refractory B-cell Non-Hodgkin's Lymphoma.MedDRA version: 21.0Level: PTClassification code 10012821Term: Diffuse large B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10029624Term: Non-Hodgkin's lymphoma unspecified histology indolent stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10029601Term: Non-Hodgkin's lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10029600Term: Non-Hodgkin's lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10029623Term: Non-Hodgkin's lymphoma unspecified histology indolent stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10029622Term: Non-Hodgkin's lymphoma unspecified histology indolent stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003408-29-GBGilead Sciences, Inc.72
已完成
1 期
Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancerKRAS or RAS wild-type metastatic colorectal cancerJPRN-UMIN000015475onprofit Organization Japan Clinical Cancer Research Organization18